{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "currency": "USD", "exchange": "NMS", "shortName": "Jounce Therapeutics, Inc.", "longName": "Jounce Therapeutics, Inc.", "messageBoardId": "finmb_228489698", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 0.0, "regularMarketPrice": 1.88, "marketState": "REGULAR", "regularMarketChange": 0.0, "regularMarketTime": 1683144004, "regularMarketDayHigh": 1.93, "regularMarketDayRange": "1.88 - 1.93", "regularMarketDayLow": 1.88, "regularMarketVolume": 11600631, "regularMarketPreviousClose": 1.88, "bid": 1.89, "ask": 1.93, "bidSize": 418, "askSize": 407, "fullExchangeName": "NasdaqGS", "financialCurrency": "USD", "regularMarketOpen": 1.92, "averageDailyVolume3Month": 3408844, "averageDailyVolume10Day": 1955051, "fiftyTwoWeekLowChange": 1.3027, "fiftyTwoWeekLowChangePercent": 2.256539, "fiftyTwoWeekRange": "0.5773 - 5.37", "fiftyTwoWeekHighChange": -3.4899998, "fiftyTwoWeekHighChangePercent": -0.6499069, "fiftyTwoWeekLow": 0.5773, "fiftyTwoWeekHigh": 5.37, "earningsTimestamp": 1678458120, "earningsTimestampStart": 1690979400, "earningsTimestampEnd": 1691411400, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -0.96, "epsForward": -1.03, "epsCurrentYear": -0.96, "priceEpsCurrentYear": -1.9583334, "sharesOutstanding": 52635500, "bookValue": 3.542, "fiftyDayAverage": 1.63977, "fiftyDayAverageChange": 0.24022996, "fiftyDayAverageChangePercent": 0.14650223, "twoHundredDayAverage": 1.927253, "twoHundredDayAverageChange": -0.047253013, "twoHundredDayAverageChangePercent": -0.024518324, "marketCap": 101586360, "forwardPE": -1.8252428, "priceToBook": 0.5307736, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "3.0 - Hold", "firstTradeDateMilliseconds": 1485527400000, "priceHint": 4, "tradeable": false, "cryptoTradeable": false, "displayName": "Jounce Therapeutics", "symbol": "JNCE"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "780 Memorial Drive", "city": "Cambridge", "state": "MA", "zip": "02139", "country": "United States", "phone": "857 259 3840", "fax": "888 459 2940", "website": "https://jouncetx.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. It develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. The company is also developing JTX-8064, a monoclonal antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; and Pimivalimab, an anti-PD-1 antibody for combination therapy. In addition, its preclinical products are JTX-1484, a monoclonal antibody designed to reduce myeloid-mediated immune suppression; and JTX-2134, a monoclonal antibody designed to reduce myeloid-mediated immune suppression and activate T and NK cells. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.", "fullTimeEmployees": 141, "companyOfficers": [{"maxAge": 1, "name": "Ms. Kimberlee Cobleigh Drapkin C.P.A., CPA", "age": 54, "title": "Pres, CFO & Treasurer", "yearBorn": 1968, "fiscalYear": 2020, "totalPay": {"raw": 582388, "fmt": "582.39k", "longFmt": "582,388"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 1132130, "fmt": "1.13M", "longFmt": "1,132,130"}}, {"maxAge": 1, "name": "Dr. James Patrick Allison Ph.D.", "title": "Founder", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Thomas F.  Gajewski M.D., Ph.D.", "title": "Founder", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Robert D. Schreiber Ph.D.", "title": "Founder", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Drew Mark Pardoll M.D., Ph.D.", "title": "Founder", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Padmanee  Sharma M.D., Ph.D.", "title": "Founder", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Louis M. Weiner M.D.", "age": 70, "title": "Founder", "yearBorn": 1952, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Komal  Joshi", "title": "Head of Investor Relations & Strategic Fin.", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Jacquelyn Fahey Sandell", "title": "Chief Legal Officer & Corp. Sec.", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Eric  Laub", "title": "VP of Investor Relations, Corp. Communications & Media Relations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 5, "boardRisk": 6, "compensationRisk": 7, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1609372800, "maxAge": 86400}}], "error": null}}